Joel S Ross MD FACP Co-Founder
Dr Ross has an extensive background in conducting clinical trials. He has worked as the Principal Investigator on over 140 clinical trials. He is very expert in how to design, implement and analyze clinical study reports. He has authored a primer called, "Principal Investigator or Practically Invisible" It is free on line to all researchers around the world and has received high praise from both industry and investigators. Dr Ross was the first fellowship trained geriatric physician in New Jersey. Dr Ross is the co editor of the book "Salsalate" along with with Dr Rainsford and Dr Hasan
Izhar Hasan MD Ph.D.
Dr. Hasan, a primary & urgent care physician, is board certified in family medicine with a subspeciality certification in clinical informatics. He has strong academic interests and has a PhD in medical informatics. He is also the founder of a proprietary software for Continuous professional development and medical school education platform called "Clinical Pearl" to be used globally to improve the quality of education of healthcare professionals. He has presented in research work in conferences, most recently in Oxford university. Dr Hasan has extensively published in journals such Lancet, Cancer research, and pediatric neurosurgery. His work has been published about Nitric oxide-NSAIDS compounds in early part of his career and Dr Hasan strongly believes in the pluripotent properties of Salsalate with new formulation.
Professor K.D. Rainsford
Professor Rainsford is Emeritus Professor of Biomedical Sciences and the Editor-in-Chief of the journal, INFLAMMOPHARMACOLOGY. He has authored over 25 books on anti-inflammatory agents and is considered a world expert in the field of medications related to inflammation.
Joseph D'Souza Ph.D
Dr. D'Souza has been working in the pharmaceutical arena for over 30 years with Novartis and UCB. He helped launch two blockbuster epilepsy medications with sales that total to date of 5 billion dollars. He is very familiar in the regulatory processes required to result in FDA and EMA (European Medicinal Agency) approval